Execs On The Move: New Chiefs At Neurotech, Photocure
An early investor in the Australian neurostimulation and neuro-diagnostic company Neurotech International is now the firm's CEO. And Photocure, focused on photodynamic technology for bladder cancer, hired a new chief executive from Ablynx.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.